Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.

Authors :: Levi S
Bronstein Y
Goldschmidt N
Morabito F
Ziv-Baran T
Del Poeta G
Bairey O
Del Principe MI
Fineman R
Mauro FR
Gutwein O
Reda G
Ruchlemer R
Sportoletti P
Laurenti L
Shvidel L
Coscia M
Tadmor T
Varettoni M
Aviv A
Murru R
Braester A
Chiarenza A
Visentin A
Pietrasanta D
Loseto G
Zucchetto A
Bomben R
Olivieri J
Neri A
Rossi D
Gaidano G
Trentin L
Foà R
Cuneo A
Perry C
Gattei V
Gentile M
Herishanu Y
Source :: American journal of hematology [Am J Hematol] 2023 Feb; Vol. 98 (2), pp. E24-E27. Date of Electronic Publication: 2022 Nov 25.
Publication Year :: 2023

Subjects :: Humans
Rituximab therapeutic use
Cyclophosphamide therapeutic use
Vidarabine therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy

Full Text Access

Tools